STX - Ticker AI Digest

Shield Therapeutics plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (STX) 1
STX 16:07
Shield Therapeutics plc
Result of AGM
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
STX 06:02
Shield Therapeutics plc
Licence Agreement in Japan for ACCRUFeR®
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics plc has entered into an exclusive license agreement with VITAL-NET, Inc. for the commercialization of ACCRUFeR® in Japan. Shield will receive an initial payment of ~$665,000, regulatory and sales milestones, and double-digit royalties on net sales. VITAL-NET will be responsible for all costs related to achieving marketing authorization and commercialization in Japan. The agreement expands Shields global footprint and addresses the prevalent health concern of iron deficiency in Japan. ACCRUFeR® is a novel oral therapy for iron deficiency with or without anemia, with patent coverage until the mid-2030s.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
STX 06:07
Shield Therapeutics plc
Audited results for the year ended 31 Dec 2024
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics, a commercial-stage pharmaceutical company specializing in iron deficiency, released its audited financial results for the year ended December 31, 2024. The company reported significant revenue growth, with total net revenues and other income reaching $32.3 million, a substantial increase from $17.5 million in 2023. This growth was primarily driven by the strong performance of ACCRUFeR®, Shields flagship product, which generated $29.3 million in net revenues, reflecting a 153% increase compared to the previous year.
During the final quarter of 2024, Shield strengthened its balance sheet by securing $10 million in equity funding, which was received in January 2025. This, along with cost-saving measures, is expected to help the company achieve its goal of becoming cash flow positive by the end of 2025. The companys loss for the year decreased to $27.2 million compared to $33.3 million in 2023.
In terms of operational highlights, Shield made significant progress in commercializing ACCRUFeR® in the US through its partnership with Viatris Inc., with prescriptions nearly doubling and the average net price increasing. The company also advanced its global development programs, with regulatory approvals and launches in Canada and the Republic of Korea, as well as ongoing Phase 3 studies in China and for the pediatric program.
Shield Therapeutics financial review highlights revenue growth, cost of sales, and selling, general, and administrative expenses. The companys cash position decreased to $6.5 million as of December 31, 2024, but additional funding received in January 2025 strengthened its financial position. The company expects to achieve positive cash flow by the end of 2025 through continued growth in ACCRUFeR® net revenues and global expansion.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
STX 16:07
Shield Therapeutics plc
Result of AGM
STX 06:07
Shield Therapeutics plc
Audited results for the year ended 31 Dec 2024
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics, a commercial-stage pharmaceutical company specializing in iron deficiency, released its audited financial results for the year ended December 31, 2024. The company reported significant revenue growth, with total net revenues and other income reaching $32.3 million, a substantial increase from $17.5 million in 2023. This growth was primarily driven by the strong performance of ACCRUFeR®, Shields flagship product, which generated $29.3 million in net revenues, reflecting a 153% increase compared to the previous year.
During the final quarter of 2024, Shield strengthened its balance sheet by securing $10 million in equity funding, which was received in January 2025. This, along with cost-saving measures, is expected to help the company achieve its goal of becoming cash flow positive by the end of 2025. The companys loss for the year decreased to $27.2 million compared to $33.3 million in 2023.
In terms of operational highlights, Shield made significant progress in commercializing ACCRUFeR® in the US through its partnership with Viatris Inc., with prescriptions nearly doubling and the average net price increasing. The company also advanced its global development programs, with regulatory approvals and launches in Canada and the Republic of Korea, as well as ongoing Phase 3 studies in China and for the pediatric program.
Shield Therapeutics financial review highlights revenue growth, cost of sales, and selling, general, and administrative expenses. The companys cash position decreased to $6.5 million as of December 31, 2024, but additional funding received in January 2025 strengthened its financial position. The company expects to achieve positive cash flow by the end of 2025 through continued growth in ACCRUFeR® net revenues and global expansion.
STX 06:02
Shield Therapeutics plc
Licence Agreement in Japan for ACCRUFeR®
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Shield Therapeutics plc has entered into an exclusive license agreement with VITAL-NET, Inc. for the commercialization of ACCRUFeR® in Japan. Shield will receive an initial payment of ~$665,000, regulatory and sales milestones, and double-digit royalties on net sales. VITAL-NET will be responsible for all costs related to achieving marketing authorization and commercialization in Japan. The agreement expands Shields global footprint and addresses the prevalent health concern of iron deficiency in Japan. ACCRUFeR® is a novel oral therapy for iron deficiency with or without anemia, with patent coverage until the mid-2030s.

AI Crunch

Single-Ticker AI Crunch
STX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Shield Therapeutics plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full STX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for STX on 2025-05-22.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
99897128
Enterprise Value
21404362
Public Float
26.34
Broker Target
17.333
Shares Out
1068418471
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BYV81293
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-22
Net Debt
18520745.0
Cash
11625232.0
EPS
-0.01
Net Income
-18025406.0
Revenue
50743741.0
Enterprise Value
21404362
Trailing PE
-
Forward PE
65.3595
Price Sales TTM
2.01
Price Book MRQ
76.3287
EV Revenue
3.0919
EV EBITDA
-1.4946

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
1068418471
Public Hands
26.34
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit STX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-05-22 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Shield Therapeutics plc has fresh news flow feeding the chart narrative.
16:07 Today's Catalyst Result of AGM
AI Charts Studio
STX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-05-22 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 319.59%
RSI Gauge
Price Change
AI Forecast